Conquer Study Start-Up Delays With a Data-Driven Approach

August 3, 2018

For over 25 years, study start-ups have plagued the pharmaceutical industry. These delays keep potentially lifesaving drugs from the patients who need them and increase costs for the R&D industry.

With so much at stake, why hasn’t the problem been solved? It hasn’t been from a lack of effort, but rather from the lack of comprehensive data and analytic tools that help operational teams predict outcomes and develop risk mitigation strategies. Gaps in key performance and quality data plus a lack of optimal processes have made it difficult to access and aggregate data into a usable format to inform decisions and improve outcomes.

Today, advances in computing and analytic capabilities enable aggregation of various public and licensed data sources to provide insights that simply did not exist before. A new approach to solving start-up delays is built on this foundation of advanced data analytics and accelerates study start-up timelines by 33 percent.

Read the rest of this article by above, or by downloading the PDF.

Previous Flipbook
IRBs can make the most of central IRB partnerships
IRBs can make the most of central IRB partnerships

The IRB at Inova Health System of Falls Church, VA, began working with a central IRB 15 years ago. Since th...

Next Flipbook
FDA Posts First List of Surrogate Endpoints
FDA Posts First List of Surrogate Endpoints

Request a Genetics in Clinical Trials training session

What You'll Learn